Novartis, Amgen and the Banner Alzheimer’s Institute announced they are halting two pivotal Phase II/III clinical trials in the Alzheimer’s Prevention Initiative Generation Program.
A new discovery at the Feinstein Institutes for Medical Research could have implications in the way diabetes is treated in the future.
Research from three clinical trials supports that Sarepta Therapeutics’ Exondys 51 slows respiratory decline in DMD.
GlaxoSmithKline Plc’s two-drug HIV regimen Dovato was successful in suppressing the AIDS-causing virus in patients over 48 weeks at the same level of a previous three-drug treatment in a late-stage trial.
Intra-Cellular Therapies Inc.’s lead drug failed to meet the main goal of a late-stage study in patients with major depressive episodes associated with bipolar disorder.
Obese people who engaged in resistance training were more likely to see reductions in a type of heart fat, a new study finds.
Older adults with slightly elevated blood sugar – sometimes called “prediabetes” – usually do not develop full-blown diabetes, a Swedish study suggests.
Pfizer’s IV Revatio, when added to inhaled nitric oxide, failed to meet the primary efficacy endpoint in treating newborns with persistent pulmonary hypertension in a Phase III study.
Researchers with Sanford Burnham Prebys Medical Discovery Institute in La Jolla, California, were able to grow natural-looking hair that grows through the skin using human induced pluripotent stem cells (iPSCs).
Lilly’s diabetes drug Trulicity hit the mark in a late-stage trial showing higher doses of the medication significantly reduced A1C from baseline versus the product’s approved once-weekly usage.